Evaluating Safety and Effectiveness of Ultra-fraction Radiotherapy Before CAR-T Cell Therapy for Adults with Relapsed or Refractory Diffuse Large B Cell Lymphoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of ultra-fraction radiotherapy combined with CAR-T cell therapy in patients with relapsed or refractory diffuse large B cell lymphoma DLBCL. This single-center, single-arm study focuses on patients who have not responded to at least two lines of chemotherapy and may have failed or are ineligible for stem cell transplantation. Participants receive ultra-fraction radiotherapy as a bridging treatment before the infusion of CD19 CAR-T cells. The study involves this combined treatment approach to assess its potential benefits and risks in managing DLBCL that has returned or not responded to previous therapies. During the study, participants will be monitored for treatment response at 3 and 6 months, as well as for progression-free survival, overall survival, duration of response, relapse rate, and severe side effects over a two-year period. Evaluations include assessing measurable disease, patient safety, and therapeutic effectiveness throughout follow-up visits lasting up to two years after treatment initiation.

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL